Temocapril prevents transition to diastolic heart failure in rats even if initiated after appearance of LV hypertrophy and diastolic dysfunction

• Published in: Cardiovascular research 2003-03, Vol.57 (3), p.757-765
• Main Authors: SAKATA, Yasushi, YAMAMOTO, Kazuhiro, MANO, Toshiaki, NISHIKAWA, Nagahiro, YOSHIDA, Junichi, MIWA, Takeshi, HORI, Masatsugu, MASUYAMA, Tohru
• Format: Article
• Language: English
• Subjects: Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Animals; Antihypertensive Agents - therapeutic use; Biological and medical sciences; Calcium-Binding Proteins - biosynthesis; Calcium-Binding Proteins - genetics; Calcium-Transporting ATPases - biosynthesis; Calcium-Transporting ATPases - genetics; Cardiovascular system; Disease Progression; Fibrosis; Gene Expression Regulation - drug effects; Heart Failure - prevention & control; Hemodynamics; Hypertension - drug therapy; Hypertrophy, Left Ventricular - drug therapy; Male; Medical sciences; Miscellaneous; Pharmacology. Drug treatments; Rats; Rats, Inbred Dahl; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - genetics; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Thiazepines - therapeutic use; Ventricular Function, Left
• ISSN: 0008-6363; 1755-3245
• DOI: 10.1016/s0008-6363(02)00722-8

Congestive heart failure with left ventricular (LV) diastolic dysfunction and preserved systolic function, i.e. diastolic heart failure (DHF), is often observed in hypertensive patients. Although angiotensin converting enzyme (ACE) inhibitors are widely used as antihypertensive therapy, there is a continued controversy about long-term effect of ACE inhibition on diastolic function. The current study was designed to elucidate a therapeutic effect of ACE inhibitor, temocapril, administration initiated after LV hypertrophy (LVH) and diastolic dysfunction are evident. Dahl salt sensitive rats fed on 8% NaCl diet from 7 weeks (hypertensive DHF model) were studied at 13 weeks (n=6) or at 19 weeks following chronic administration of a subdepressor dose of temocapril (0.2 mg/kg/day, TEM(+), n=6) or placebo (TEM(-), n=7) from 13 weeks. Compensatory LVH was associated with prolonged time constant of LV relaxation (Tau) at 13 weeks. In TEM(-), progression of LVH and fibrosis and elevation of LV end diastolic pressure were observed at 19 weeks. Administration of temocapril from 13 weeks prevented the further progression of LVH and fibrosis, attenuated increases in myocardial stiffness constant and Tau, and prevented the development of DHF. These effects were accompanied with the attenuation of decreases in sarcoplasmic reticulum calcium(2+)-ATPase 2a and phosphorylated phospholamban and of hypertrophic signalings' upregulation. This study demonstrated that chronic administration of temocapril exerts a therapeutic effect on diastolic dysfunction and prevents the transition to DHF even if initiated after appearance of LVH and diastolic dysfunction.